De Puy Inc. v. Biomedical Engineering Trust

216 F. Supp. 2d 358, 2001 WL 1683021
CourtDistrict Court, D. New Jersey
DecidedApril 18, 2001
Docket2:97-cv-03450
StatusPublished
Cited by11 cases

This text of 216 F. Supp. 2d 358 (De Puy Inc. v. Biomedical Engineering Trust) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
De Puy Inc. v. Biomedical Engineering Trust, 216 F. Supp. 2d 358, 2001 WL 1683021 (D.N.J. 2001).

Opinion

OPINION

LECHNER, District Judge.

This action was brought by plaintiff/counterclaim defendant DePuy Ortho-paedics, Inc. (“DePuy”) against defendants/ counterclaim plaintiffs Biomedical Engineering Trust, Frederick F. Buechel, M.D. and Michael J. Pappas, Ph.D., PE (as trustees of certain trusts entitled Biomedical Engineering Trust and Biomedical Engineering Trust II) (collectively, “BET”). BET sought damages for an alleged breach by DePuy of its obligation to pay royalties to BET on sales of orthopedic products outside the United States. The instant matter was tried to a jury, and DePuy was awarded $25 million in damages. On 28 September 2000, judgment (the “Judgment”) was entered against De-Puy in the amount of “twenty-five million dollars ($25,000,000.00), plus preand, or, post-judgment interest, as permitted by the court, to be determined at a latter date.” Judgment at 2.

Currently before the court is the motion by DePuy for judgment as a matter of law (the “Motion for Judgment as a Matter of Law”), pursuant to Rule 50(b) of the Federal Rules of Civil Procedure (“Rule 50(b)”), or, in the alternative, for a new trial (the “Motion for a New Trial”) or remittitur (the “Motion for Remittitur”) (collectively, the “DePuy Post Trial Motions”). 1 Also before the court is the motion of BET to amend the Judgment to include prejudgment and, or, post-judgment interest (the “BET Motion to Amend the Judgment”), 2 pursuant to Rule 59(e) of the Federal Rules of Civil Procedure (“Rule 59(e)”). Oral argument was conducted on 25 January 2001, at which *362 time supplemental briefing was requested. Such supplemental briefs were received on 9 February 2001.

For the reasons set forth below, the DePuy Post Trial Motions are denied and the BET Motion to Amend the Judgment is granted.

Facts

A. Parties

DePuy, formally known as DePuy Incorporated, is an Indiana corporation with its principal place of business in Warsaw, Indiana. DePuy manufactures and distributes orthopedic products.

Frederick F. Buechel, M.D. (“Buechel”) and Michael J. Pappas, Ph.D., PE (“Pap-pas”) are residents of New Jersey. Bue-chel and Pappas are the trustees of Biomedical Engineering Trust (“Trust I”). 3 Buechel and Pappas are also the trustees of Biomedical Engineering Trust II.

Buechel is an orthopedic surgeon. Bue-chel is also a Clinical Professor of Orthopedic Surgery and a Chief of Total Reconstructive and Arthritis Surgery Services at the University of Medicine and Dentistry, New Jersey Medical School.

Pappas has a doctorate in mechanical engineering and is a professional engineer. In addition, Pappas is a Professor Emeritus at the New Jersey Institute of Technology and an adjunct professor of surgery at the University of Medicine and Dentistry, New Jersey Medical School.

B. Licensing Agreements

1. First License Agreement

On 25 April 1977, DePuy, through its corporate predecessor DePuy, a Division of BioDynamics, Inc. (“BIO”), entered into a license agreement (the “First License Agreement”) with BEC.

Under the First License Agreement, BEC, as licensor, owned “all right, title and interest in and on a new and useful orthopaedic device called Floating Center Shoulder Prosthesis [ (the “FCSP”) ] covered by U.S. Patent # 3916451, and a certain new and useful orthopaedic device called NJ Knee [(the “NJ Knee”)], [collectively, the “Devices”].... ” First License Agreement at 1.

Pursuant to the terms of the First License Agreement, BEC granted BIO, as licensee, an exclusive license to manufacture, sell and distribute the Devices, and to sub-license others to sell and distribute the Devices. Id. at ¶ 1. The term “licensee” under the First License Agreement encompassed BIO and “its parent, affiliate, and/or subsidiary companies whenever the context permits or requires.” Id. (clause 1).

The First License Agreement also stated BIO “agree[d] to pay to [BEC] a royalty at the rate of ten per cent (10%) of the list price of [the FCSP] and fifteen per cent (15%) of the list price of the said NJ Knee on each of [the Devices] made and sold by [BIO] or by any sub-licensee of [BIO], said list price to be the current list price on the date of the execution of this contract.” Id. at ¶ 2. Pursuant to the First License Agreement, “the list price of each of [the Devices] shall be fixed by [BIO] and [BIO] shall have full power and authority to change the same from time to time by either raising or lowering the same as it shall see fit.” Id. at ¶ 5.

In addition, pursuant to the First License Agreement, BIO was required to “render calendar quarterly statements to [BEC] on the 30th day of each calendar month following a calendar quarterly *363 showing the number of [the Devices] made and sold by it during the preceding calendar quarterly.” Id. at ¶ 4. The Devices, moreover, were deemed sold under the First License Agreement when payment was received by BIO, either from a purchaser, or from a sub-licensee. Id. at ¶ 6.

2. Amendment to the First License Agreement

BEC and BIO subsequently entered into an amendment to the First License Agreement, effective 9 December 1977, (the “Amendment to the First License Agreement”). Amendment to the First License Agreement at 1. The Amendment to the First License Agreement replaced a mistaken reference to “licensor” with “licensee” in paragraph 2 of the First License Agreement. Id. The Amendment to the First License Agreement also changed the “current list price” definition for calculating royalties due under the First License Agreement. 4 Id. In light of the Amendment to the First License Agreement, royalties due under the First License Agreement were no longer based on the current list price of the Devices as of the date of the First License Agreement. Id. Instead, under the Amendment to the First License Agreement, royalty calculations were based on “the list price currently in effect at the time royalties are paid to [BEC] and shall be based on the current list price of either [BIO] or any sub-licensee whichever is higher.” Id.

3. Second License Agreement

On 24 July 1979, BEC and BIO entered into a second license agreement (the “Second License Agreement”). Second License Agreement at 1. The Second License Agreement cancelled the First License Agreement. Id. (clause 2). In contrast to the First License Agreement, the Second License Agreement was between “[BEC] ... (hereinafter referred to as Licensor) and [BIO] ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Culwick v. Wood
384 F. Supp. 3d 328 (E.D. New York, 2019)
Fendi Adele S.R.L. v. Burlington Coat Factory Warehouse Corp.
867 F. Supp. 2d 427 (S.D. New York, 2012)
Franciose v. Jones
907 N.E.2d 139 (Indiana Court of Appeals, 2009)
DIALAMERICA v. KeySpan Energy
865 A.2d 728 (New Jersey Superior Court App Division, 2005)
Competitive Technologies v. Fujitsu Ltd.
286 F. Supp. 2d 1118 (N.D. California, 2003)
Lithuanian Commerce Corp. v. Sara Lee Hosiery
202 F. Supp. 2d 371 (D. New Jersey, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
216 F. Supp. 2d 358, 2001 WL 1683021, Counsel Stack Legal Research, https://law.counselstack.com/opinion/de-puy-inc-v-biomedical-engineering-trust-njd-2001.